From:	Trials
To:	Nate Luman; Trials
Cc:	ssukduang@cooley.com; jcousin@cooley.com; jdavies@cooley.com; iagarwal@cooley.com; BoxDRFPGL.001LP; 2esf; 2Pjm
Subject:	RE: IPR2024-01197 - request to expunge incorrect version of Exhibit 1002
Date:	Wednesday, August 21, 2024 1:11:43 PM

Counsel,

From the Board –

Petitioner's request to expunge the incorrect version of Ex. 1002 is granted. The incorrect version of Exhibit 1002, filed on July 22, shall be expunged from the record.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Nate Luman <Nate.Luman@knobbe.com>
Sent: Thursday, August 15, 2024 1:43 PM
To: Trials <Trials@USPTO.GOV>
Cc: ssukduang@cooley.com; jcousin@cooley.com; jdavies@cooley.com; iagarwal@cooley.com; BoxDRFPGL.001LP <BoxDRFPGL.001LP@knobbe.com>; 2esf <2esf@knobbe.com>; 2Pjm <2Pjm@knobbe.com>
Subject: IPR2024-01197 - request to expunge incorrect version of Exhibit 1002

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Members of the Board,

Petitioner Dr. Falk Pharma inadvertently filed an incorrect version of Exhibit 1002 on July 22 in IPR2024-01197. Petitioner filed a corrected version of Exhibit 1002 (Dohil, US20070111978) on July 23, which is attached to this email. Petitioner requests that the Board expunge the incorrect version of Exhibit 1002 from the record.

Counsel for Patent Owner Ellodi timely filed its mandatory notices on August 12. The parties conferred via email, and Patent Owner does not oppose this request. Counsel for Patent Owner is included on this email.

Sincerely,
Nate

Nathanael R. Luman, Ph.D.

Partner
Nate.Luman@knobbe.com
858-707-4235 **Direct**
Knobbe Martens
3579 Valley Centre Drive, Suite 300
San Diego, CA 92130
www.knobbe.com/nate-luman

NOTICE: This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.